There are two major hurdles that must be overcome before cancer gene therapy becomes a clinical reality: tumor-specific therapeutic gene activation and efficient delivery of gene therapy vectors into the tumor mass. The ability to specifically activate therapeutic genes in cancer cells is what differentiates gene therapy from conventional cancer therapies. In the previous funding cycle, we have made substantial progress in developing a novel gene therapy approach by which therapeutic genes can be regulated by hyperthermia. We have shown that therapeutic genes can be regulated by hyperthermia in a very efficient and targeted fashion in the tumor mass with impressive anti-tumor efficacy in experimental tumor models. However, we are still faced with the problem of inefficient delivery of the gene therapy vectors, which can serious hinder the application of our otherwise very promising strategy. In this application, we want to build upon our previous successes and continue to improve our hyperthermia-regulated gene therapy approach. We will deal with both the regulation issue and the delivery issue for gene therapy. A two-pronged approach will be employed. On the one hand, we will continue to explore new gene regulation approaches that may further improve/enhance our heat-induced therapeutic gene activation strategy. On the other hand, we will tackle the gene delivery issue by developing hyperthermia-regulated replication competent adenovirus vectors that can selectively replicate in the tumor mass. In particular, we will have two specific aims.
In specific aim 1, we will develop a novel gene regulation strategy that may further enhance hyperthermia-activated therapeutic gene expression. For this specific aim, we will attempt to design a novel Cre-lox based irreversible genetic switch that can potentially enhance the regulation and expression of heat-activated gene therapy.
In specific aim 2, we will develop conditionally replicative adenovirus vectors with virus replication under the control of hyperthermia or hypoxia. We will engineer recombinant adenovirus vectors that can selectively replicate in hyperthermia-treated tumor cells or those that can selectively replicate in hypoxic tumor cells. The well-known anti-angiogenic gene endostatin will be engineered into the vectors. The vectors will then be evaluated for their anti-tumor efficacy either alone or in combination with hyperthermia and/or ionizing radiation. At the end of the new funding cycle, we hope to make significant advancement in both the delivery and the regulation of the hyperthermia-mediated gene therapy approach, thereby making it even closer to clinical human cancer treatment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA081512-05A1
Application #
6682102
Study Section
Radiation Study Section (RAD)
Program Officer
Stone, Helen B
Project Start
1999-04-02
Project End
2008-06-30
Budget Start
2003-08-13
Budget End
2004-06-30
Support Year
5
Fiscal Year
2003
Total Cost
$231,000
Indirect Cost
Name
Duke University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Li, Wenrong; Li, Fang; Huang, Qian et al. (2008) Noninvasive imaging and quantification of epidermal growth factor receptor kinase activation in vivo. Cancer Res 68:4990-7
Li, Fang; Sonveaux, Pierre; Rabbani, Zahid N et al. (2007) Regulation of HIF-1alpha stability through S-nitrosylation. Mol Cell 26:63-74
Dewhirst, Mark W; Cao, Yiting; Li, Chuan Yuan et al. (2007) Exploring the role of HIF-1 in early angiogenesis and response to radiotherapy. Radiother Oncol 83:249-55
Liu, Yunbo; Kon, Takashi; Li, Chuanyuan et al. (2006) High intensity focused ultrasound-induced gene activation in solid tumors. J Acoust Soc Am 120:492-501
Chuang, Eric Y; Chen, Xi; Tsai, Mong-Hsun et al. (2006) Abnormal gene expression profiles in unaffected parents of patients with hereditary-type retinoblastoma. Cancer Res 66:3428-33
Liu, Shanling; Wang, He; Yang, Zhonghui et al. (2005) Enhancement of cancer radiation therapy by use of adenovirus-mediated secretable glucose-regulated protein 94/gp96 expression. Cancer Res 65:9126-31
Wang, Y; Yang, Z; Liu, S et al. (2005) Characterisation of systemic dissemination of nonreplicating adenoviral vectors from tumours in local gene delivery. Br J Cancer 92:1414-20
Wang, Yong; Liu, Shanling; Li, Chuan-Yuan et al. (2005) A novel method for viral gene delivery in solid tumors. Cancer Res 65:7541-5
Liu, Yunbo; Kon, Takashi; Li, Chuanyuan et al. (2005) High intensity focused ultrasound-induced gene activation in sublethally injured tumor cells in vitro. J Acoust Soc Am 118:3328-36
Cao, Yiting; Li, Chuan-Yuan; Moeller, Benjamin J et al. (2005) Observation of incipient tumor angiogenesis that is independent of hypoxia and hypoxia inducible factor-1 activation. Cancer Res 65:5498-505

Showing the most recent 10 out of 23 publications